Canadian CANNAINVESTOR Magazine May 2017 - Page 237


In fact the long chain fatty acid molecule conjugation with cannabinoids delivers another benefit that could entirely disrupt the cannabis edibles market worldwide. Already-performed in vitro studies conducted in Philadelphia in the summer of 2015 showed as much as a 499% increase in absorption of cannabinoids across human intestinal tissue. This means that, when this technology is used, smaller amounts of cannabinoids ingested as edibles can deliver as much or more to the bloodstream, and do so more quickly and consistently.

The market consequences of this could be quite profound since edibles are among the fastest growing cannabis market segments, in some areas accounting for as much as 50% of all cannabis sold. It’s no surprise that this trend is expected to continue, since edibles that utilize this technology also enjoy flavor benefits and a big reduction in cannabis odor.

Cannabis edibles that act quickly and consistently, and allow for lower doses to achieve the desired effect, could be as impactful to the regulated cannabis industry as Tesla has been to the auto industry. Simply stated: cannabis growers might need to grow far less raw material than they expected if this technology is widely adopted since low doses of 2mg to 10mg per serving are generally sufficient for many consumers.

Adoption of technology has changed virtually every industrial and business sector on earth, and it is naïve to think it won’t have major impacts in the cannabis sector as well. Lexaria Bioscience Corp is the company that has developed this edibles technology, for which it has already received patent protection in the USA and in Australia. It is patent pending in over 40 additional countries.